Solventum Corporation (NYSE:SOLV – Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock investors purchased 3,171 call options on the company. This represents an increase of approximately 1,153% compared to the typical volume of 253 call options.
Solventum Stock Performance
SOLV traded up $6.10 on Tuesday, hitting $86.57. 535,453 shares of the company’s stock were exchanged, compared to its average volume of 1,396,965. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The stock has a fifty day moving average of $77.55 and a two-hundred day moving average of $74.16. Solventum has a twelve month low of $62.38 and a twelve month high of $88.20. The firm has a market cap of $14.99 billion, a PE ratio of 10.56, a P/E/G ratio of 1.20 and a beta of 0.66.
Solventum (NYSE:SOLV – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.Solventum’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts anticipate that Solventum will post 6.58 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Solventum
Wall Street Analyst Weigh In
A number of research analysts have commented on SOLV shares. UBS Group upgraded shares of Solventum from a “neutral” rating to a “buy” rating and set a $95.00 price objective on the stock in a research note on Tuesday. Weiss Ratings upgraded shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. BTIG Research reaffirmed a “buy” rating and set a $91.00 price target on shares of Solventum in a research report on Monday, July 13th. Wells Fargo & Company lowered their price objective on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. Finally, Stifel Nicolaus reduced their target price on Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $86.00.
View Our Latest Report on Solventum
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.
Further Reading
- Five stocks we like better than Solventum
- 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys?
- Whirlpool’s Report May Show How Frozen the Housing Market Really Is
- 3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks
- 5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest?
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
